Investigation of a new parameter in chronic lymphocytic leukemia: The percentage of large peripheral lymphocytes determined by the Hemalog D

Binet, Jacques; Vaugier, G; Dighiero, Guillaume; d’Athis, Philippe; Charron, Dominique

doi:10.1016/0002-9343(77)90152-8

Cited by 49 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was some variation in the pattern of the LUC population as seen on the oscilloscope display, indicating varia tion in cell size. Binet et al [4] compared the ratio of LUC to the total number of lymphocytes in CLL and control subjects, and found that the CLL patients with values higher than the control range were those with advanced disease in their clinical stag ing system. Our small number of patients in this group has not allowed us to confirm or refute these findings.…”

Section: Discussionmentioning

confidence: 99%

Use of the Hemalog D Automated Leucocyte Differential Counter in the Diagnosis and Therapy of Leukaemia

Hinchliffe¹,

Lilleyman²,

Burrows³

et al. 1981

Acta Haematol

View full text Add to dashboard Cite

Of 46 adult patients with active leukaemia whose white cells were examined using a Hemalog D automated differential leucocyte counter, 45 showed abnormalities indicative of their disease, and the odd one out would not have been missed due to associated thrombocytopenia. Sequential studies while on chemotherapy allowed rapid and accurate neutrophil counts to be performed even in the presence of profound leucopenia and the re-emergence of blast cells in some cases was detected 2–3 weeks earlier than by microscopy. These findings indicate that the Hemalog D is reliable in the detection and can be useful in the follow-up of patients with leukaemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of the Hemalog D Automated Leucocyte Differential Counter in the Diagnosis and Therapy of Leukaemia

Hinchliffe¹,

Lilleyman²,

Burrows³

et al. 1981

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Although CLL remains an incurable disorder, early stage detection and treatment can control disease progression, whereas late stage patients are often unresponsive to various treatments (4). Even though CLL often presents with a heterogeneous pathology in the clinic, most patients receive a few standardized treatments, primarily on the basis of limited clinical parameters such as Rai or Binet staging, which classify CLL patients on the basis of the spreading of the disease and its cytogenetic characterization, underlining the need for more informative diagnostic markers with better clinical significance (5,6).…”

mentioning

confidence: 99%

MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia

Moussay

Wang

Cho

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

162

130

View full text Add to dashboard Cite

Early cancer detection and disease stratification or classification are critical to successful treatment. Accessible, reliable, and informative cancer biomarkers can be medically valuable and can provide some relevant insights into cancer biology. Recent studies have suggested improvements in detecting malignancies by the use of specific extracellular microRNAs (miRNAs) in plasma. In chronic lymphocytic leukemia (CLL), an incurable hematologic disorder, sensitive, early, and noninvasive diagnosis and better disease classification would be very useful for more effective therapies. We show here that circulating miRNAs can be sensitive biomarkers for CLL, because certain extracellular miRNAs are present in CLL patient plasma at levels significantly different from healthy controls and from patients affected by other hematologic malignancies. The levels of several of these circulating miRNAs also displayed significant differences between zeta-associated protein 70 (ZAP-70) + and ZAP-70 − CLL. We also determined that the level of circulating miR-20a correlates reliably with diagnosis-totreatment time. Network analysis of our data, suggests a regulatory network associated with BCL2 and ZAP-70 expression in CLL. This hypothesis suggests the possibility of using the levels of specific miRNAs in plasma to detect CLL and to determine the ZAP-70 status.hairy cell leukemia | multiple myeloma | gene network | NR6A1

show abstract

“…To this end, it has been suggested that differ ences in cell size [2,[4][5][6][7][8] and enzyme activities [9][10][11][12] of the circulating B-CLL lymphocytes may relate to the different clinical behaviour of the disease. In a previous report [13], an attempt was made to evaluate the activity of lymphocyte adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and lactate dehydrogenase (LDH) in two morphological subgroups of B-CLL classified according to the per centage of circulating large non-granular atypical lymphocytes (AL).…”

Section: Introductionmentioning

confidence: 99%

Relationship between Lymphocyte Size and Enzyme Activities in Two Morphological Variants of B-Chronic Lymphocytic Leukaemia

Corrons¹,

Colomer²,

Pujades³

et al. 1989

Acta Haematol

View full text Add to dashboard Cite

The activities of the key glycolytic enzymes phosphofructokinase (PFK), pyruvate kinase (PK) and hexokinase in addition to adenosine deaminase, purine nucleoside phosphorylase (PNP) and lactate dehy-drogenase (LDH) have been measured in lymphocytes from 39 cases with B-chronic lymphocytic leukaemia (B-CLL). According to the percentage of circulating large non-granular atypical lymphocytes (AL) the B-CLL cases were classified as: typical ( < 10% of AL; 28 cases) and atypical (10-25% AL; 11 cases). In both groups the median lymphocyte volume (MLV) was assessed and correlated with the correspondent enzyme activities.The MLV of B-CLL lymphocytes was significantly (p < 0.001) decreased (149.9 ± 19.4 fl) as compared to normal B lymphocytes (175.1 + 14.5 fl) and it was significantly (p < 0.001) lower in typical B-CLL (141.8 ± 12.2 fl) than in atypical B-CLL (172.0 ± 17.2 fl). Furthermore, in patients with typical B-CLL, all enzyme activities when expressed as U/109 cells were, with the exception of PFK, significantly decreased compared to normal B lymphocytes. However, when the results were expressed as U/ml cells, only PK, PNP and LDH remained significantly low.These findings demonstrate that the determination of MLV in addition to morphology may be a useful tool to distinguish the two previously described morphological B-CLL variants (typical and atypical) and that these two different B-CLL groups are also distinguishable on the basis of three enzyme activities, PK, PNP and LDH which have been shown to be less dependent on cell size than the other enzymes, also studied here.

show abstract

Investigation of a new parameter in chronic lymphocytic leukemia: The percentage of large peripheral lymphocytes determined by the Hemalog D

Cited by 49 publications

References 15 publications

Use of the Hemalog D Automated Leucocyte Differential Counter in the Diagnosis and Therapy of Leukaemia

Use of the Hemalog D Automated Leucocyte Differential Counter in the Diagnosis and Therapy of Leukaemia

MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia

Relationship between Lymphocyte Size and Enzyme Activities in Two Morphological Variants of B-Chronic Lymphocytic Leukaemia

Contact Info

Product

Resources

About